MarginsXMarginsX
Home › Markets › Health Care › NVO

Novo Nordisk A/S (NVO)

NVO trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$41.60
-0.07% on the day
Market cap
$184.2B
Large cap
Revenue · 2025
$45.7B
+6.4% on 2024
Net income · 2025
$15.1B
33.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/353278/000035327826000012/0000353278-26-000012-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from DKK at 6.7640 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerNVO on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryDenmark
IPO yearNot reported by the screener
SEC CIK0000353278
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$45.7B
Net income$15.1B
Operating income$18.9B
Net margin33.1%
Operating margin41.3%
Revenue growth+6.4%
Cash$3.9B
Total assets$80.3B
P/E (computed)12.2×
P/S (computed)4.0×

Reported in DKK; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
26.5B DKK cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed February 4, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-04
Cash and burn26.5B DKK cash; operating cash flow 29.8B DKK a quarter.Report 2025-12-31
Shares outstanding4,465,000,000 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, DenmarkPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
309.1B DKK102.4B DKK119.1B DKK26.5B DKK131.0B DKK309.1B DKK20-F 2026-02-04
FY 2024
2024-12-31
290.4B DKK101.0B DKK121.0B DKK15.7B DKK102.8B DKK290.4B DKK20-F 2026-02-04
FY 2023
2023-12-31
232.3B DKK83.7B DKK108.9B DKK14.4B DKK27.0B DKK232.3B DKK20-F 2026-02-04
FY 2022
2022-12-31
177.0B DKK55.5B DKK78.9B DKK12.7B DKK25.8B DKK177.0B DKK20-F 2025-02-05
FY 2021
2021-12-31
140.8B DKK47.8B DKK55.0B DKK10.7B DKK26.6B DKK140.8B DKK20-F 2024-01-31
FY 2020
2020-12-31
126.9B DKK42.1B DKK52.0B DKK12.2B DKK10.4B DKK126.9B DKK20-F 2023-02-01
FY 2019
2019-12-31
122.0B DKK39.0B DKK46.8B DKK15.4B DKK4.5B DKK122.0B DKK20-F 2022-02-02

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in DKK.

Key SEC documents

DocumentFormFiled
Latest annual report20-F2026-02-04
Latest quarterly / interim
FORM 6-K
6-K2026-11-16

Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.3%
1 month+9.4%
3 months-10.9%
Year to date-18.2%
1 year-15.3%
From 52-week high-34.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ABTAbbott Laboratories$107.45-0.99%$186.1B
PFEPfizer Inc.$28.86-0.10%$164.5B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B
AZNAstraZeneca PLC$184.02-0.23%$285.4B
SNYSanofi ADS$48.39+0.04%$118.0B
NVSNovartis AG$160.20-0.19%$305.7B
GSKGSK plc$50.41-0.08%$102.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier